{"id":"W4405319926","doi":"10.1002/jha2.1062","title":"Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Baker Hughes (Canada); McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Merck Canada; McGill University Health Centre; Ottawa Hospital Research Institute; London Health Sciences Centre; McGill University","keywords":"Pembrolizumab; Medicine; Regimen; Cyclophosphamide; Internal medicine; Oncology; Immunotherapy; Clinical trial; ELISPOT; Lymphoma; Chemotherapy; Immune system; Immunology; T cell; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002400672,0.0002624652,0.0004318707,0.00008687591,0.0001186619,0.00007380152,0.000157356,0.0001197391,0.0001709501],"category_scores_gemma":[0.0001031609,0.0001619744,0.0001290791,0.0002522365,0.0001219792,0.0001118517,0.00007772358,0.0001579436,0.00003064209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001301904,"about_ca_system_score_gemma":0.0002257139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002882567,"about_ca_topic_score_gemma":0.00006574321,"domain_scores_codex":[0.998354,0.0000917603,0.0004353109,0.0003980133,0.0004072644,0.0003136488],"domain_scores_gemma":[0.9987822,0.0003396081,0.0001334857,0.0005198003,0.00008433301,0.0001405818],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5446594,0.002492722,0.3877277,0.0002970196,0.0006217227,0.000309716,0.00388538,3.97354e-8,0.003801927,0.00001938659,0.007221126,0.04896387],"study_design_scores_gemma":[0.1077257,0.001914317,0.862105,0.0005589325,0.0002347278,0.000008007936,0.00007234635,0.000005103385,0.001343502,0.000005326915,0.02581496,0.0002121141],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937845,0.00290672,0.00003071155,0.0003634164,0.001235181,0.000956054,0.0004874605,0.0000654454,0.0001705417],"genre_scores_gemma":[0.9938055,0.0007544341,0.00004642506,0.0006516832,0.0002519659,0.00003885356,0.0001276231,0.00006096248,0.004262614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4743773,"threshold_uncertainty_score":0.6605123,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01066533123460231,"score_gpt":0.242737969926255,"score_spread":0.2320726386916527,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}